Support PenkeGilead Sciences Inc - Trending symbols
Latest News of Gilead Sciences Inc
| Date | Title | Read |
|---|---|---|
| 2025-09-11 23:50 | Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider | Read |
| 2025-09-11 21:25 | Biotechs Could Benefit If RFK Jr. Leaves HHS | Read |
| 2025-09-11 20:37 | Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite | Read |
| 2025-09-10 06:59 | Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating | Read |
| 2025-09-08 12:57 | Nutrien to sell 50% equity position in Profertil | Read |
| 2025-09-06 07:13 | Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy | Read |
| 2025-09-05 20:04 | Validea Detailed Fundamental Analysis - GILD | Read |
| 2025-09-04 16:46 | Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva | Read |
| 2025-09-03 18:15 | Gilead starts building manufacturing hub under $32 billion planned US investments | Read |
| 2025-09-03 17:30 | Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy | Read |
Trends
| 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Other Comprehensive Income | 93,000 | -20,000 | 73,000 | 59,000 | 132,000 | -40,000 | 92,000 | -110,000 | -18,000 | |
| Net Debt | 20,476,000 | 102,000 | 20,578,000 | -2,366,000 | 18,212,000 | -1,492,000 | 16,720,000 | -24,646,000 | -7,926,000 | |
| Long-term Assets Other | 5,586,000 | -1,544,000 | 4,042,000 | 18,000 | 4,060,000 | 1,435,000 | 5,495,000 | -7,763,000 | -2,268,000 | |
| Depreciation and Amortization | 684,000 | 4,000 | 688,000 | 2,000 | 690,000 | 4,000 | 694,000 | -2,078,000 | -1,384,000 | |
| Gross Profit | 5,485,000 | 70,000 | 5,555,000 | -421,000 | 5,134,000 | 271,000 | 5,405,000 | -15,866,200 | -10,461,200 | |
| Income before Tax | 1,300,000 | 288,000 | 1,588,000 | 730,000 | 2,318,000 | -665,000 | 1,653,000 | -6,139,000 | -4,486,000 | |
| Tax Provision | 316,000 | 233,000 | 549,000 | -403,000 | 146,000 | 91,000 | 237,000 | -552,000 | -315,000 | |
| Income Tax Expense | 316,000 | 233,000 | 549,000 | -403,000 | 146,000 | 90,000 | 236,000 | -551,000 | -315,000 | |
| Net Income | 1,010,000 | 35,000 | 1,045,000 | 1,135,000 | 2,180,000 | -751,000 | 1,429,000 | -5,599,000 | -4,170,000 | |
| Net Income from Continuing Operations | 985,000 | 54,000 | 1,039,000 | 1,133,000 | 2,172,000 | -756,000 | 1,416,000 | -5,587,000 | -4,171,000 | |
| EBITDA | 2,011,000 | 43,000 | 2,054,000 | 587,000 | 2,641,000 | 498,000 | 3,139,000 | -7,461,000 | -4,322,000 | |
| Net Working Capital | 3,844,000 | -2,397,000 | 1,447,000 | 2,621,000 | 4,068,000 | 737,000 | 4,805,000 | -5,070,000 | -265,000 | |
| Net non Operating Income Other | -284,000 | 108,000 | -176,000 | 166,000 | -10,000 | -164,000 | -174,000 | 326,000 | 152,000 | |
| Minority Interest | 9,000 | -6,000 | 3,000 | 4,000 | 7,000 | 19,000 | 26,000 | -32,000 | -6,000 | |
| Other Assets | 1,000 | 0 | 1,000 | 5,555,000 | 5,556,000 | -5,555,000 | 1,000 | -2,000 | -1,000 | |
| Retained Earnings | 16,324,000 | -1,338,000 | 14,986,000 | 131,000 | 15,117,000 | 639,000 | 15,756,000 | -15,925,900 | -169,900 | |
| EBIT | 1,003,000 | -910,000 | 93,000 | 1,661,000 | 1,754,000 | 910,000 | 2,664,000 | -2,671,400 | -7,400 | |
| Operating Income | 940,000 | -743,000 | 197,000 | 1,832,000 | 2,029,000 | 808,000 | 2,837,000 | -2,849,200 | -12,200 | |
| Cost of Revenue | 2,627,000 | -1,203,000 | 1,424,000 | 18,000 | 1,442,000 | -47,000 | 1,395,000 | -1,395,500 | -500 | |
| Total Other Income Expense Net | -181,000 | -168,000 | -349,000 | -177,000 | -526,000 | 121,000 | -405,000 | 410,000 | 5,000 | |
| Other Current Assets | 1,908,000 | -429,000 | 1,479,000 | 532,000 | 2,011,000 | 130,000 | 2,141,000 | -3,170,000 | -1,029,000 | |
| Minority Interest | 19,000 | -7,000 | 12,000 | -5,000 | 7,000 | -6,000 | 1,000 | -6,000 | -5,000 |
Comments
How you think about this?